BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients wi ...
The drug did not induce adverse events more commonly seen with erdafitinib, a drug typically used to treat the disease that targets all four FGFR isoforms.
A leading pharma company approved DelveInsight to prioritize the ESMO coverage specifically on dMMR/ MSIH, BRAF mutated, FGFR mutated and KRAS mutated GI tumors to understand KOL’s perspective ...
Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025• APEX trial enrollment in AdvSM patients complete; top-line results ...
Recent research shows the bird flu virus may be just a few mutations away from transmitting more readily to humans, which could elevate risk. If you haven’t yet been sick this winter ...
Having two copies of the MTHFR gene mutation may raise your risk for certain health conditions, though more research is needed. You may have the mutation and not find out unless you undergo ...
Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback